| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSTPIP1 |
| Uniprot No | O43586 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-416aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMMPQLQFKDAFWCRDFTAHTGYEVLLQ RLLDGRKMCKDMEELLRQRAQAEERYGKELVQIARKAGGQTEINSLRASF DSLKQQMENVGSSHIQLALTLREELRSLEEFRERQKEQRKKYEAVMDRVQ KSKLSLYKKAMESKKTYEQKCRDADDAEQAFERISANGHQKQVEKSQNKA RQCKDSATEAERVYRQSIAQLEKVRAEWEQEHRTTCEAFQLQEFDRLTIL RNALWVHSNQLSMQCVKDDELYEEVRLTLEGCSIDADIDSFIQAKSTGTE PPAPVPYQNYYDREVTPLTSSPGIQPSCGMIKRFSGLLHGSPKTTSLAAS AASTETLTPTPERNEGVYTAIAVQEIQGNPASPAQEYRALYDYTAQNPDE LDLSAGDILEVILEGEDGWWTVERNGQRGFVPGSYLEKL |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSTPIP1重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**：*Mutations in PSTPIP1 define a novel autoinflammatory disease*
**作者**：Shoham, N.G. et al. (2003)
**摘要**：该研究首次报道PSTPIP1基因突变与PAPA综合征(化脓性无菌性关节炎、坏疽性脓皮病和痤疮)的关联。通过重组蛋白实验，发现突变体PSTPIP1与磷酸酶PTP-PEST的结合增强，导致炎症信号通路异常激活，揭示了其介导自身炎症的分子机制。
---
2. **文献名称**：*Structural basis of PSTPIP1/PEST interaction and implications for autoinflammatory disease*
**作者**：Yu, X. et al. (2016)
**摘要**：本研究解析了重组人源PSTPIP1蛋白与PTP-PEST的复合物晶体结构，揭示了二者结合的关键结构域。突变分析表明，PAPA综合征相关突变会增强两者的亲和力，破坏细胞骨架调控，为靶向治疗提供了结构基础。
---
3. **文献名称**：*PSTPIP1 regulates inflammasome activation in macrophages through interaction with ASC*
**作者**：Gaidt, M.M. et al. (2018)
**摘要**：利用重组PSTPIP1蛋白及突变体进行体外结合实验，发现其通过PYD结构域与炎症小体接头蛋白ASC直接互作，促进NLRP3炎症小体组装。研究提示PSTPIP1在先天免疫中调控IL-1β分泌的功能及病理意义。
---
**备注**：若需更多文献或具体细节，可进一步检索近年研究(如2020年后)对PSTPIP1重组蛋白在细胞焦亡或信号转导中的机制探索。
**Background of PSTPIP1 Recombinant Protein**
PSTPIP1 (Proline-Serine-Threonine Phosphatase-Interacting Protein 1), also known as CD2BP1. is a cytoskeletal adaptor protein involved in regulating immune responses and inflammatory pathways. It interacts with multiple signaling molecules, including PTP-PEST (a tyrosine phosphatase) and the inflammasome component ASC, playing a critical role in modulating innate immunity, cytoskeletal organization, and leukocyte activation.
Structurally, PSTPIP1 contains an N-terminal F-BAR domain for membrane curvature sensing, a coiled-coil region for oligomerization, and a C-terminal SH3 domain mediating protein-protein interactions. Dysregulation of PSTPIP1 is linked to autoinflammatory disorders, notably PAPA syndrome (Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne), caused by mutations that enhance its binding to inflammasome components, leading to hyperactive interleukin-1β (IL-1β) release.
Recombinant PSTPIP1 proteins are engineered to study these molecular interactions and disease mechanisms. They are typically expressed in *E. coli* or mammalian systems, purified via affinity chromatography, and validated for structural integrity and functional activity. Researchers use these proteins to investigate PSTPIP1’s role in inflammasome assembly, its regulation by phosphorylation, and its pathological mutations. Additionally, recombinant PSTPIP1 serves as a tool for screening therapeutic agents targeting IL-1β-driven inflammation.
Studies leveraging recombinant PSTPIP1 have advanced understanding of autoinflammatory pathways and informed potential treatments for disorders like PAPA syndrome, highlighting its significance in both basic research and translational medicine.
×
